Equities analysts expect that Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Rating) will report earnings of ($0.68) per share for the current quarter, according to Zacks. Four analysts have made estimates for Y-mAbs Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.76) and the highest estimate coming in at ($0.61). Y-mAbs Therapeutics posted earnings […]
Y-mAbs Therapeutics (NASDAQ:YMAB – Get Rating)‘s stock had its “outperform” rating reissued by investment analysts at Wedbush in a report released on Tuesday, RTT News reports. They currently have a $21.00 price target on the stock, down from their previous price target of $28.00. Wedbush’s price objective would suggest a potential upside of 109.37% from […]
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Rating) has received a consensus rating of “Buy” from the seven brokerages that are currently covering the stock, Marketbeat.com reports. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1-year price target among brokers that […]
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Rating) saw unusually large options trading on Thursday. Stock traders acquired 4,281 call options on the company. This is an increase of approximately 3,071% compared to the average volume of 135 call options. YMAB has been the topic of a number of research analyst reports. JPMorgan Chase & Co. […]